Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

Yu Sun, Judith Campisi, Celestia Higano, Tomasz (Tom) Beer, Peggy Porter, Ilsa Coleman, Lawrence True, Peter S. Nelson

    Research output: Contribution to journalArticle

    374 Citations (Scopus)

    Abstract

    Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments are recognized to profoundly influence cellular phenotypes, including susceptibilities to toxic insults. Using a genome-wide analysis of transcriptional responses to genotoxic stress induced by cancer therapeutics, we identified a spectrum of secreted proteins derived from the tumor microenvironment that includes the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B). We determined that WNT16B expression is regulated by nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB) after DNA damage and subsequently signals in a paracrine manner to activate the canonical Wnt program in tumor cells. The expression of WNT16B in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. These results delineate a mechanism by which genotoxic therapies given in a cyclical manner can enhance subsequent treatment resistance through cell nonautonomous effects that are contributed by the tumor microenvironment.

    Original languageEnglish (US)
    Pages (from-to)1359-1368
    Number of pages10
    JournalNature Medicine
    Volume18
    Issue number9
    DOIs
    StatePublished - Sep 2012

    Fingerprint

    Tumor Microenvironment
    Tumors
    Prostatic Neoplasms
    DNA Damage
    Neoplasms
    Cells
    Poisons
    Therapeutics
    Genes
    Disease Progression
    Prostate
    Cell Survival
    B-Lymphocytes
    Chemotherapy
    Genome
    Morbidity
    Phenotype
    Light
    Drug Therapy
    Peptides

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)
    • Medicine(all)

    Cite this

    Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. / Sun, Yu; Campisi, Judith; Higano, Celestia; Beer, Tomasz (Tom); Porter, Peggy; Coleman, Ilsa; True, Lawrence; Nelson, Peter S.

    In: Nature Medicine, Vol. 18, No. 9, 09.2012, p. 1359-1368.

    Research output: Contribution to journalArticle

    Sun, Y, Campisi, J, Higano, C, Beer, TT, Porter, P, Coleman, I, True, L & Nelson, PS 2012, 'Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B', Nature Medicine, vol. 18, no. 9, pp. 1359-1368. https://doi.org/10.1038/nm.2890
    Sun, Yu ; Campisi, Judith ; Higano, Celestia ; Beer, Tomasz (Tom) ; Porter, Peggy ; Coleman, Ilsa ; True, Lawrence ; Nelson, Peter S. / Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. In: Nature Medicine. 2012 ; Vol. 18, No. 9. pp. 1359-1368.
    @article{f3c90657888f4d4da816bb068c304fdb,
    title = "Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B",
    abstract = "Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments are recognized to profoundly influence cellular phenotypes, including susceptibilities to toxic insults. Using a genome-wide analysis of transcriptional responses to genotoxic stress induced by cancer therapeutics, we identified a spectrum of secreted proteins derived from the tumor microenvironment that includes the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B). We determined that WNT16B expression is regulated by nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB) after DNA damage and subsequently signals in a paracrine manner to activate the canonical Wnt program in tumor cells. The expression of WNT16B in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. These results delineate a mechanism by which genotoxic therapies given in a cyclical manner can enhance subsequent treatment resistance through cell nonautonomous effects that are contributed by the tumor microenvironment.",
    author = "Yu Sun and Judith Campisi and Celestia Higano and Beer, {Tomasz (Tom)} and Peggy Porter and Ilsa Coleman and Lawrence True and Nelson, {Peter S.}",
    year = "2012",
    month = "9",
    doi = "10.1038/nm.2890",
    language = "English (US)",
    volume = "18",
    pages = "1359--1368",
    journal = "Nature Medicine",
    issn = "1078-8956",
    publisher = "Nature Publishing Group",
    number = "9",

    }

    TY - JOUR

    T1 - Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

    AU - Sun, Yu

    AU - Campisi, Judith

    AU - Higano, Celestia

    AU - Beer, Tomasz (Tom)

    AU - Porter, Peggy

    AU - Coleman, Ilsa

    AU - True, Lawrence

    AU - Nelson, Peter S.

    PY - 2012/9

    Y1 - 2012/9

    N2 - Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments are recognized to profoundly influence cellular phenotypes, including susceptibilities to toxic insults. Using a genome-wide analysis of transcriptional responses to genotoxic stress induced by cancer therapeutics, we identified a spectrum of secreted proteins derived from the tumor microenvironment that includes the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B). We determined that WNT16B expression is regulated by nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB) after DNA damage and subsequently signals in a paracrine manner to activate the canonical Wnt program in tumor cells. The expression of WNT16B in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. These results delineate a mechanism by which genotoxic therapies given in a cyclical manner can enhance subsequent treatment resistance through cell nonautonomous effects that are contributed by the tumor microenvironment.

    AB - Acquired resistance to anticancer treatments is a substantial barrier to reducing the morbidity and mortality that is attributable to malignant tumors. Components of tissue microenvironments are recognized to profoundly influence cellular phenotypes, including susceptibilities to toxic insults. Using a genome-wide analysis of transcriptional responses to genotoxic stress induced by cancer therapeutics, we identified a spectrum of secreted proteins derived from the tumor microenvironment that includes the Wnt family member wingless-type MMTV integration site family member 16B (WNT16B). We determined that WNT16B expression is regulated by nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB) after DNA damage and subsequently signals in a paracrine manner to activate the canonical Wnt program in tumor cells. The expression of WNT16B in the prostate tumor microenvironment attenuated the effects of cytotoxic chemotherapy in vivo, promoting tumor cell survival and disease progression. These results delineate a mechanism by which genotoxic therapies given in a cyclical manner can enhance subsequent treatment resistance through cell nonautonomous effects that are contributed by the tumor microenvironment.

    UR - http://www.scopus.com/inward/record.url?scp=84868633053&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84868633053&partnerID=8YFLogxK

    U2 - 10.1038/nm.2890

    DO - 10.1038/nm.2890

    M3 - Article

    VL - 18

    SP - 1359

    EP - 1368

    JO - Nature Medicine

    JF - Nature Medicine

    SN - 1078-8956

    IS - 9

    ER -